Fair Value Measurement

12 Months Ended

Dec. 31, 2017

The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands):



	December 31, 2017								December 31, 2016
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	36,086		—		—		36,086		133,540		—		—		133,540
Total assets at fair value	$	36,086	$	—	$	—	$	36,086	$	133,540	$	—	$	—	$	133,540
Liabilities:
Contingent consideration	—		—		24,301		24,301		—		—		5,175		5,175
Deferred consideration	—		223,158		—		223,158		—		—		—		—
Total liabilities at fair value	$	—	$	223,158	$	24,301	$	247,459	$	—	$	—	$	5,175	$	5,175

There were no transfers of assets or liabilities between Level 1, Level 2 and Level 3 categories of the fair value hierarchy during the years ended December 31, 2017 and 2016.

The Company used Level 1 inputs to determine the fair value of its cash equivalents, which primarily consist of funds held in government money market accounts and commercial paper. As such, the carrying value of cash equivalents approximates fair value. As of December 31, 2017 and 2016, the carrying value of cash equivalents was $36.1 million and $133.5 million, respectively.

In connection with the acquisition of the BNP Business, the Company will pay up to $280.0 million in cash, of which $256.0 million is guaranteed and is considered deferred consideration and $24.0 million is contingent consideration. The fair value of the deferred consideration was determined to be $220.6 million on the acquisition date based on the net present value of cash payments using an estimated borrowing rate using a quoted price for a similar liability. The Company recorded 2.6 million for the accretion of interest on the deferred consideration in the fourth quarter of 2017. The fair value of contingent consideration on the acquisition date was $19.7 million and was calculated using a discounted probability weighted valuation model.

In conjunction with the acquisitions of BioHelix Corporation in May 2013, AnDiaTec GmbH & Co. KG in August 2013 and Immutopics, Inc. in March 2016, the Company recorded contingent consideration of $4.6 million as of December 31, 2017 and $5.2 million as of December 31, 2016. The Company assesses the fair value of contingent consideration to be settled in cash related to these prior acquisitions using a discounted revenue model. Significant assumptions used in the measurement include revenue projections and discount rates. This fair value measurement of contingent consideration is based on significant inputs not observed in the market and thus represent Level 3 measurements. Due to changes in the estimated payments and a shorter discounting period related to the various contingent consideration liabilities, the fair value of the contingent consideration changed during the years ended 2017, 2016 and 2015. These changes resulted in gains of $0.1 million, $0.5 million and $0.1 million recorded to cost of sales in the Consolidated Statements of Operations during the years ended December 31, 2017, 2016 and 2015, respectively.

Changes in estimated fair value of contingent consideration liabilities from December 31, 2016 through December 31, 2017 are as follows (in thousands):



	Contingent consideration liability (Level 3 measurement)
Balance at December 31, 2016	$	5,175
Cash payments	(498		)
Net gain recorded for fair value adjustments	(80		)
Additional liability recorded for the BNP Business	19,700
Unrealized loss on foreign currency translation	4
Balance at December 31, 2017	$	24,301

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details